Platform Technologies

The technologies being developed by Abgenics are directed towards a new generation of antibiotics and antiparasitics, using recombinant antibodies and RNA interference. Vectors for probiotic Lactobacillus mediated delivery of these molecules to the site of action is also being developed. This entails the development of antibody libraries directed against specific pathogens and fusing them with potent antimicrobials to increase their efficacy (Abtid®).